Starling Oncology (STLN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Starling Oncology (STLN) do?
Starling Oncology Inc (STLN) is a U.S.-listed company in Healthcare (Medical Care Facilities). What it does: Operates outpatient cancer care clinics and administers specialty oncology pharmacy services. Treats patients through value-based Medicare insurance arrangements and direct physician visits. Operates outpatient cancer clinics that manage treatment costs through capitated Medicare contracts and proprietary. It is worth $324.33M on the market and sold $623.71M over the last year.
- Market cap
- $324.33M
- P/E ratio
- None (reported a loss)
- Annual sales
- $623.71M
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Brief updated
- Nov 15, 2026
Brands and businesses behind STLN
- Starling Nexus: A proprietary care management platform that coordinates cancer therapies and controls treatment utilization under insurance risk contracts.
STLN’s flags, in plain English
Each flag is a number from Starling Oncology’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Still Climbing
Sales up 21.8% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Insiders Hold
Insiders own 30% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Cheap on Cash Flow
Priced at 17.2 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Burning Cash
Losing money, profit margin of -4.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about STLN
How big is Starling Oncology?
Starling Oncology’s market cap is $324.33M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $623.71M: what customers paid the company over the last year, before any costs.
What is STLN’s P/E ratio?
STLN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with STLN?
Rising specialty drug acquisition costs compress operating margins across fee-for-service treatment protocols. That is one risk on Starling Oncology’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Starling Oncology’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. STLN’s filings on SEC.gov. The Margin Monkey is research, not advice.
